Clinical Trials Logo

Smouldering Myeloma clinical trials

View clinical trials related to Smouldering Myeloma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03673826 Active, not recruiting - Smouldering Myeloma Clinical Trials

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM

HO147SMM
Start date: November 19, 2018
Phase: Phase 2
Study type: Interventional

Randomized (2:1) multi-center open-label phase II trial. Patients with high-risk SMM will be enrolled on the study and treated with KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9) or Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).